Literature DB >> 28619756

Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes.

Anirudh Sattiraju1, Xiaobing Xiong1, Darpan N Pandya2, Thaddeus J Wadas1,2, Ang Xuan3, Yao Sun1, Youngkyoo Jung1, Kiran Kumar Solingapuram Sai1, Jay F Dorsey4, King C Li1, Akiva Mintz5,6.   

Abstract

Glioblastoma (GBM) is the most common primary malignant astrocytoma characterized by extensive invasion, angiogenesis, hypoxia, and micrometastasis. Despite the relatively leaky nature of GBM blood vessels, effective delivery of antitumor therapeutics has been a major challenge due to the complications caused by the blood-brain barrier (BBB) and the highly torturous nature of newly formed tumor vasculature (blood tumor barrier-BTB). External beam radiotherapy was previously shown to be an effective means of permeabilizing central nervous system (CNS) barriers. By using targeted short-ranged radionuclides, we show for the first time that our targeted actinium-225-labeled αvβ3-specific liposomes (225Ac-IA-TLs) caused catastrophic double stranded DNA breaks and significantly enhanced the permeability of BBB and BTB in mice bearing orthotopic GBMs. Histologic studies revealed characteristic α-particle induced double strand breaks within tumors but was not significantly present in normal brain regions away from the tumor where BBB permeability was observed. These findings indicate that the enhanced vascular permeability in these distal regions did not result from direct α-particle-induced DNA damage. On the basis of these results, in addition to their direct antitumor effects, 225Ac-IA-TLs can potentially be used to enhance the permeability of BBB and BTB for effective delivery of systemically administered antitumor therapeutics. Mol Cancer Ther; 16(10); 2191-200. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28619756      PMCID: PMC5628117          DOI: 10.1158/1535-7163.MCT-16-0907

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 2.  Targeting dormant micrometastases: rationale, evidence to date and clinical implications.

Authors:  Robert E Hurst; Anja Bastian; Lora Bailey-Downs; Michael A Ihnat
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

3.  Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor.

Authors:  Christopher A Burnett; Jianwu Xie; Jade Quijano; Zhimin Shen; Finie Hunter; Monica Bur; King C P Li; S Narasimhan Danthi
Journal:  Bioorg Med Chem       Date:  2005-06-01       Impact factor: 3.641

4.  Partially polymerized liposomes: stable against leakage yet capable of instantaneous release for remote controlled drug delivery.

Authors:  Guoting Qin; Zheng Li; Rongmin Xia; Feng Li; Brian E O'Neill; Jessica T Goodwin; Htet A Khant; Wah Chiu; King C Li
Journal:  Nanotechnology       Date:  2011-03-10       Impact factor: 3.874

Review 5.  Molecular targeted α-particle therapy for oncologic applications.

Authors:  Thaddeus J Wadas; Darpan N Pandya; Kiran Kumar Solingapuram Sai; Akiva Mintz
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

6.  Principles of nanoparticle design for overcoming biological barriers to drug delivery.

Authors:  Elvin Blanco; Haifa Shen; Mauro Ferrari
Journal:  Nat Biotechnol       Date:  2015-09       Impact factor: 54.908

7.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

8.  High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe.

Authors:  Ruimin Huang; Stefan Harmsen; Jason M Samii; Hazem Karabeber; Kenneth L Pitter; Eric C Holland; Moritz F Kircher
Journal:  Theranostics       Date:  2016-05-07       Impact factor: 11.556

9.  Glioblastoma multiforme therapy and mechanisms of resistance.

Authors:  Yulian P Ramirez; Jessica L Weatherbee; Richard T Wheelhouse; Alonzo H Ross
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25

10.  Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Authors:  Darpan N Pandya; Roy Hantgan; Mikalai M Budzevich; Nancy D Kock; David L Morse; Izadora Batista; Akiva Mintz; King C Li; Thaddeus J Wadas
Journal:  Theranostics       Date:  2016-03-01       Impact factor: 11.556

View more
  12 in total

Review 1.  Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS.

Authors:  Benjamin J Umlauf; Eric V Shusta
Journal:  Curr Opin Biotechnol       Date:  2019-03-05       Impact factor: 9.740

2.  Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.

Authors:  Anirudh Sattiraju; Akiva Mintz
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.682

Review 4.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

5.  VCAM-1 targeted alpha-particle therapy for early brain metastases.

Authors:  Aurélien Corroyer-Dulmont; Samuel Valable; Nadia Falzone; Anne-Marie Frelin-Labalme; Ole Tietz; Jérôme Toutain; Manuel Sarmiento Soto; Didier Divoux; Laurent Chazalviel; Elodie A Pérès; Nicola R Sibson; Katherine A Vallis; Myriam Bernaudin
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 13.029

6.  Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.

Authors:  Janik Puttemans; Yana Dekempeneer; Jos L Eersels; Heleen Hanssens; Pieterjan Debie; Marleen Keyaerts; Albert D Windhorst; Frank van der Aa; Quentin Lecocq; Karine Breckpot; Alfred Morgenstern; Frank Bruchertseifer; Tony Lahoutte; Nick Devoogdt; Matthias D'Huyvetter
Journal:  Cancers (Basel)       Date:  2020-04-21       Impact factor: 6.639

Review 7.  Development of Targeted Alpha Particle Therapy for Solid Tumors.

Authors:  Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 8.  Nanoparticles as immunomodulators and translational agents in brain tumors.

Authors:  Adam J Grippin; Kyle A Dyson; Sadeem Qdaisat; James McGuiness; Brandon Wummer; Duane A Mitchell; Hector R Mendez-Gomez; Elias J Sayour
Journal:  J Neurooncol       Date:  2020-08-05       Impact factor: 4.130

Review 9.  Immunotherapy for Pediatric Brain Tumors.

Authors:  Elias J Sayour; Duane A Mitchell
Journal:  Brain Sci       Date:  2017-10-21

10.  Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.

Authors:  Darpan N Pandya; Akesh Sinha; Hong Yuan; Lysette Mutkus; Kristina Stumpf; Frank C Marini; Thaddeus J Wadas
Journal:  Molecules       Date:  2020-08-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.